On October 8, China signed an agreement with the Global Alliance for Vaccines and Immunization to officially join the ‘COVID-19 Vaccine Implementation Program.’ This is an important step for China in practicing the concept of a community of shared human health and in fulfilling its commitment to promoting vaccines as a global public good.
According to CCTV reports, once China’s vaccine development is completed and put into use, it will be considered a global public good and will be prioritized for developing countries.
Wu Guizhen, the chief biosafety expert of the Chinese Center for Disease Control and Prevention, said that vaccines from four companies in China have entered Phase III clinical trials, and some have reached the end of Phase III. This means that high-risk populations in China may soon be able to use these vaccines.
It is reported that regarding COVID-19 vaccines, China has successively deployed five parallel technological routes for development, including inactivated vaccines, recombinant protein vaccines, and adenovirus vector vaccines.
Currently, four vaccines have entered Phase III clinical trials, including three inactivated vaccines and one adenovirus vector vaccine.
According to experts, China’s COVID-19 vaccine is expected to be available by the end of this year.
